Imatinib mesylate and nilotinib affect MHC-class I presentation by modulating the proteasomal processing of antigenic peptides-Reference-Cited by-同舟云学术

Imatinib mesylate and nilotinib affect MHC-class I presentation by modulating the proteasomal processing of antigenic peptides

Published:2012-11-25 Issue:4 Volume:62 Page:715-726
ISSN:0340-7004
Container-title:Cancer Immunology, Immunotherapy
language:en
Short-container-title:Cancer Immunol Immunother

Author:

Held Stefanie Andrea Erika,Duchardt Katharina Maria,Tenzer Stefan,Rückrich Thomas,von Schwarzenberg Karin,Bringmann Anita,Kurts Christian,Schild Hansjörg,Driessen Christoph,Brossart Peter,Heine Annkristin

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Immunology,Immunology and Allergy

Link

http://link.springer.com/content/pdf/10.1007/s00262-012-1373-7.pdf

Reference45 articles.

1. Lugo TG, Pendergast AM, Muller AJ, Witte ON (1990) Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 247:1079–1082

2. Heisterkamp N, Jenster G, ten Hoeve J, Zovich D, Pattengale PK, Groffen J (1990) Acute leukaemia in bcr/abl transgenic mice. Nature 344:251–253. doi: 10.1038/344251a0

3. Hochhaus A, O’Brien SG, Guilhot F et al (2009) Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 23:1054–1061. doi: 10.1038/leu.2009.38

4. Kantarjian HM, O’Brien S, Cortes J et al (2003) Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data. Cancer 98:2636–2642. doi: 10.1002/cncr.11831

5. Roy L, Guilhot J, Krahnke T et al (2006) Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials. Blood 108:1478–1484. doi: 10.1182/blood-2006-02-001495

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The BCR-ABL inhibitor nilotinib influences phenotype and function of monocyte-derived human dendritic cells;Cancer Immunology, Immunotherapy;2018-02-21

2. Novel Antigen Targets for Immunotherapy of Acute Myeloid Leukemia;Current Drug Targets;2017-01-24

3. The VEGF-Receptor Inhibitor Axitinib Impairs Dendritic Cell Phenotype and Function;PLOS ONE;2015-06-04

4. A TCR-mimic antibody to WT1 bypasses tyrosine kinase inhibitor resistance in human BCR-ABL+ leukemias;Blood;2014-05-22

5. The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo;Blood;2013-08-15